Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare ConferenceBusiness Wire • 05/02/23
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)Business Wire • 05/01/23
Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response RateBusiness Wire • 05/01/23
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt SalesZacks Investment Research • 04/27/23
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 04/26/23
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector ProductionBusiness Wire • 04/26/23
Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria GroupZacks Investment Research • 04/25/23
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer PatientsBusiness Wire • 04/20/23
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple MyelomaBusiness Wire • 04/17/23
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic DevelopmentBusiness Wire • 04/11/23